talazoparib,enzalutamide
astellas,pfizer
[]
 this class of drugs is disappointing but perhaps opens the door for future scientific exploration. some of the trial design for parp inhibitors has been particularly poor making conclusions difficult
Medical Director LCC Cancer Center, Medical Director Cancer Genetics, Investigator Clinical Cancer Trials,IRB, Professor, Cancer Committee